Research Article
Bioinformatics Analysis Identifies EPAS1 as a Novel Prognostic Marker Correlated with Immune Infiltration in Acute Myeloid Leukemia
Table 1
Demographic and clinicopathological characteristics of AML patients based on EPAS1 expression level.
| | Characteristics | Frequency (%) | EPAS1 expression | | | Low () | High () |
| | Age | | 56.00 [43.75,64.25] | 57.00 [41.50,69.00] | 0.549b | | Gender | | | | 0.284 | | Female | 68 (45.0) | 38 (50.0) | 30 (40.0) | | | Male | 83 (55.0) | 38 (50.0) | 45 (60.0) | | | Race | | | | 0.564a | | Asian | 1 (0.7) | 1 (1.3) | 0 (0.0) | | | Black or African American | 13 (8.7) | 8 (10.5) | 5 (6.8) | | | White | 135 (90.6) | 67 (88.2) | 68 (93.2) | | | Cytogenetic risk | | | | 0.001 | | Favorable | 31 (20.8) | 8 (10.7) | 23 (31.1) | | | Intermediate | 82 (55.0) | 52 (69.3) | 30 (40.5) | | | Poor | 36 (24.2) | 15 (20.0) | 21 (28.4) | | | Cytogenetics | | | | 0.002,a | | +8 | 8 (5.9) | 3 (4.2) | 5 (7.8) | | | Complex | 24 (17.8) | 10 (14.1) | 14 (21.9) | | | del (5) | 1 (0.7) | 1 (1.4) | 0 (0.0) | | | del (7) | 6 (4.4) | 3 (4.2) | 3 (4.7) | | | inv (16) | 8 (5.9) | 0 (0.0) | 8 (12.5) | | | Normal | 69 (51.1) | 46 (64.8) | 23 (35.9) | | | (15; 17) | 11 (8.1) | 3 (4.2) | 8 (12.5) | | | (8; 21) | 7 (5.2) | 4 (5.6) | 3 (4.7) | | | (9; 11) | 1 (0.7) | 1 (1.4) | 0 (0.0) | | | FAB classifications | | | | 0.048,a | | M0 | 15 (10.0) | 11 (14.5) | 4 (5.4) | | | M1 | 35 (23.3) | 20 (26.3) | 15 (20.3) | | | M2 | 38 (25.3) | 20 (26.3) | 18 (24.3) | | | M3 | 15 (10.0) | 4 (5.3) | 11 (14.9) | | | M4 | 29 (19.3) | 11 (14.5) | 18 (24.3) | | | M5 | 15 (10.0) | 10 (13.2) | 5 (6.8) | | | M6 | 2 (1.3) | 0 (0.0) | 2 (2.7) | | | M7 | 1 (0.7) | 0 (0.0) | 1 (1.4) | | | FLT3 mutation | | | | 0.026 | | Negative | 102 (69.4) | 46 (60.5) | 56 (78.9) | | | Positive | 45 (30.6) | 30 (39.5) | 15 (21.1) | | | IDH1 R132 mutation | | | | 0.245a | | Negative | 136 (91.3) | 66 (88.0) | 70 (94.6) | | | Positive | 13 (8.7) | 9 (12.0) | 4 (5.4) | | | IDH1 R140 mutation | | | | 0.369a | | Negative | 137 (91.9) | 68 (89.5) | 69 (94.5) | | | Positive | 12 (8.1) | 8 (10.5) | 4 (5.5) | | | IDH1 R172 mutation | | | | 0.238a | | Negative | 147 (98.7) | 76 (100.0) | 71 (97.3) | | | Positive | 2 (1.3) | 0 (0.0) | 2 (2.7) | | | RAS mutation | | | | 0.276a | | Negative | 142 (94.7) | 70 (92.1) | 72 (97.3) | | | Positive | 8 (5.3) | 6 (7.9) | 2 (2.7) | | | NPM1 mutation | | | | 0.001 | | Negative | 117 (78.0) | 50 (65.8) | 67 (90.5) | | | Positive | 33 (22.0) | 26 (34.2) | 7 (9.5) | | | DNMT3A mutation | | | | 0.463 | | Negative | 92 (84.4) | 50 (87.7) | 42 (80.8) | | | Positive | 17 (15.6) | 7 (12.3) | 10 (19.2) | | | RUNX1 mutation | | | | 0.545a | | Negative | 97 (89.0) | 52 (91.2) | 45 (86.5) | | | Positive | 12 (11.0) | 5 (8.8) | 7 (13.5) | | | WBC count (×109/L) | | 31.00 [8.00,69.00] | 11.50 [3.00,33.75] | 0.001,b | | BM blasts | | 49.00 [17.75,72.50] | 17.00 [2.00,55.50] | <0.001,b | | PB blasts | | 75.00 [61.50,86.25] | 61.00 [40.00,81.00] | 0.001,b |
|
|
BM: bone marrow; PB: peripheral blood. statistically significant, . aFisher’s exact test. bWilcoxon rank sum test. |
